Local delivery of a CXCR3 antagonist decreases the progression of bone resorption induced by LPS injection in a murine model.

Soma LariSarah HiyariDavi Neto de Araújo SilvaBeatriz de Brito BezerraMakiko IshiiSepehr MonajemzadehZhong-Kai CuiSotirios TetradisMin LeeFlávia Q Pirih

Published in: Clinical oral investigations (2022)

CXCR3 blockade can be regarded as a novel target for therapeutic intervention of bone loss. It can be a safe and convenient method for periodontitis treatment or prevention applicable in clinical practice.

Keyphrases

bone loss
clinical practice
randomized controlled trial
cell migration
anti inflammatory
bone mineral density
combination therapy
postmenopausal women